US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist
  • 0.000
  • 0.0000.00%
Close Jul 26 09:30 ET
0Market Cap0.00P/E (TTM)

Actuate Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
Total revenue
0
0
0
0
Operating revenue
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
46.71%7.77M
23.59%24.97M
5.3M
20.21M
Selling and administrative expenses
17.81%912.82K
-14.51%3.27M
--774.8K
--3.82M
-General and administrative expense
17.81%912.82K
-14.51%3.27M
--774.8K
--3.82M
Research and development costs
51.65%6.86M
32.47%21.71M
--4.52M
--16.39M
Operating profit
-46.71%-7.77M
-23.59%-24.97M
-5.3M
-20.21M
Net non-operating interest income expense
-58.14%9.71K
2,754.26%309.03K
23.2K
10.83K
Non-operating interest income
-71.37%14.79K
1,204.89%352.67K
--51.65K
--27.03K
Non-operating interest expense
-82.16%5.08K
169.39%43.64K
--28.45K
--16.2K
Other net income (expense)
-10,533.29%-532.52K
-318.22%-79.82K
5.1K
36.58K
Gain on sale of security
-737.05%-32.52K
-318.22%-79.82K
--5.1K
--36.58K
Other non- operating income (expenses)
---500K
----
----
----
Income before tax
-57.41%-8.3M
-22.74%-24.74M
-5.27M
-20.16M
Income tax
Net income
-57.41%-8.3M
-22.74%-24.74M
-5.27M
-20.16M
Net income continuous Operations
-57.41%-8.3M
-22.74%-24.74M
---5.27M
---20.16M
Minority interest income
Net income attributable to the parent company
-57.41%-8.3M
-22.74%-24.74M
-5.27M
-20.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-57.41%-8.3M
-22.74%-24.74M
-5.27M
-20.16M
Basic earnings per share
-58.52%-0.54
-23.09%-1.65
-0.3407
-1.3404
Diluted earnings per share
-58.52%-0.54
-23.09%-1.65
-0.3407
-1.3404
Dividend per share
Currency Unit
USD
USD
USD
USD
(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022
Total revenue 0000
Operating revenue --0--0--0--0
Cost of revenue
Gross profit
Operating expense 46.71%7.77M23.59%24.97M5.3M20.21M
Selling and administrative expenses 17.81%912.82K-14.51%3.27M--774.8K--3.82M
-General and administrative expense 17.81%912.82K-14.51%3.27M--774.8K--3.82M
Research and development costs 51.65%6.86M32.47%21.71M--4.52M--16.39M
Operating profit -46.71%-7.77M-23.59%-24.97M-5.3M-20.21M
Net non-operating interest income expense -58.14%9.71K2,754.26%309.03K23.2K10.83K
Non-operating interest income -71.37%14.79K1,204.89%352.67K--51.65K--27.03K
Non-operating interest expense -82.16%5.08K169.39%43.64K--28.45K--16.2K
Other net income (expense) -10,533.29%-532.52K-318.22%-79.82K5.1K36.58K
Gain on sale of security -737.05%-32.52K-318.22%-79.82K--5.1K--36.58K
Other non- operating income (expenses) ---500K------------
Income before tax -57.41%-8.3M-22.74%-24.74M-5.27M-20.16M
Income tax
Net income -57.41%-8.3M-22.74%-24.74M-5.27M-20.16M
Net income continuous Operations -57.41%-8.3M-22.74%-24.74M---5.27M---20.16M
Minority interest income
Net income attributable to the parent company -57.41%-8.3M-22.74%-24.74M-5.27M-20.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -57.41%-8.3M-22.74%-24.74M-5.27M-20.16M
Basic earnings per share -58.52%-0.54-23.09%-1.65-0.3407-1.3404
Diluted earnings per share -58.52%-0.54-23.09%-1.65-0.3407-1.3404
Dividend per share
Currency Unit USDUSDUSDUSD

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg